SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

29 Jul 2025 Evaluate
Revenue showed a marginal decline at Rs. 4986.16 millions. For the quarter ended June 2025, as compared to corresponding quarter of last year.The Company has registered profit of Rs. 133.47  millions for the quarter ended June 2025, a growth of 23.20%  over Rs. 108.34 millions millions achieved in the corresponding quarter of last year.The Operating Profit of the company witnessed a decrease to 689.89 millions from 731.39 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 4986.16 5130.00 -2.80 4986.16 5130.00 -2.80 21394.23 18661.17 14.65
Other Income 17.58 80.91 -78.27 17.58 80.91 -78.27 461.88 587.11 -21.33
PBIDT 689.89 731.39 -5.67 689.89 731.39 -5.67 3086.30 2092.16 47.52
Interest 304.48 405.13 -24.84 304.48 405.13 -24.84 1459.12 1393.77 4.69
PBDT 385.41 326.26 18.13 385.41 326.26 18.13 1626.91 644.74 152.34
Depreciation 221.38 206.22 7.35 221.38 206.22 7.35 846.08 874.07 -3.20
PBT 164.03 120.04 36.65 164.03 120.04 36.65 780.83 -229.33 -440.48
TAX 30.56 11.70 161.20 30.56 11.70 161.20 189.27 13.42 1310.36
Deferred Tax 31.03 1.11 2695.50 31.03 1.11 2695.50 203.91 14.61 1295.69
PAT 133.47 108.34 23.20 133.47 108.34 23.20 591.56 -242.75 -343.69
Equity 921.63 919.17 0.27 921.63 919.17 0.27 921.63 919.00 0.29
PBIDTM(%) 13.84 14.26 -2.95 13.84 14.26 -2.95 14.43 11.21 28.67

Strides Pharma Scien Share Price

1000.00 -0.70 (-0.07%)
20-Apr-2026 14:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.40
Dr. Reddys Lab 1235.00
Cipla 1233.70
Zydus Lifesciences 939.55
Lupin 2328.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×